LATEST NEWS

Mar-18-2019

Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update

CARMIEL, Israel, March 18, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the full-year ended December 31, 2018 and provided a corporate update. “Throughout 2018 and into early 2019, we significantly advanced our clin... 
Mar-13-2019

Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call

CARMIEL, Israel, March 13, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will postpone its 2018 financial results corporate update from Thursday, March 14, 2019, to Monday, March 18, 2019 at 8:30 am ET. To participate in the conference... 
Mar-06-2019

Protalix BioTherapeutics to Hold Full-Year 2018 Financial Results and Corporate Update Conference Call on March 14, 2019

CARMIEL, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report full-year 2018 financial results and provide a corporate update on Thursday, March 14, 2019 at 8:30 am ET. To participate in the conference call, please... 
All News